

Gordon J Lockbaum

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8483713/publications.pdf>

Version: 2024-02-01

14
papers

373
citations

933447

10
h-index

996975

15
g-index

18
all docs

18
docs citations

18
times ranked

399
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. <i>Nature Communications</i> , 2022, 13, .	12.8	63
2	Unique structural solution from a VH3-30 antibody targeting the hemagglutinin stem of influenza A viruses. <i>Nature Communications</i> , 2021, 12, 559.	12.8	11
3	Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond. <i>Chemical Reviews</i> , 2021, 121, 3238-3270.	47.7	40
4	Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188. <i>Viruses</i> , 2021, 13, 174.	3.3	80
5	Inhibiting HTLV-1 Protease: A Viable Antiviral Target. <i>ACS Chemical Biology</i> , 2021, 16, 529-538.	3.4	12
6	Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode. <i>Biochemistry</i> , 2021, 60, 2925-2931.	2.5	21
7	Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 8296-8313.	6.4	6
8	Optimizing the refinement of merohedrally twinned P61 HIV-1 proteaseâ€“inhibitor cocrystal structures. <i>Acta Crystallographica Section D: Structural Biology</i> , 2020, 76, 302-310.	2.3	1
9	Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors. <i>MBio</i> , 2020, 11, .	4.1	15
10	HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2â€² Ligands To Optimize Hydrogen Bonding in the Substrate Envelope. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8062-8079.	6.4	21
11	Molecular Determinants of Epistasis in HIV-1 Protease: Elucidating the Interdependence of L89V and L90M Mutations in Resistance. <i>Biochemistry</i> , 2019, 58, 3711-3726.	2.5	15
12	Picomolar to Micromolar: Elucidating the Role of Distal Mutations in HIV-1 Protease in Conferring Drug Resistance. <i>ACS Chemical Biology</i> , 2019, 14, 2441-2452.	3.4	36
13	Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease. <i>ACS Infectious Diseases</i> , 2019, 5, 316-325.	3.8	27
14	Quinoxaline-Based Linear HCV NS3/4A Protease Inhibitors Exhibit Potent Activity against Drug Resistant Variants. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 691-696.	2.8	16